Literature DB >> 29601633

Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.

Naoko Imanishi1, Ayako Hirai1, Kazue Yoneda1, Shohei Shimajiri2, Taiji Kuwata1, Yuko Tashima1, Masahiro Takeuchi3, Yoshiko Iwai3,4, Yoshinobu Ichiki1, Fumihiro Tanaka1.   

Abstract

BACKGROUND AND OBJECTIVES: Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death-ligand 1 (PD-L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
METHODS: Twenty-six patients with surgically resected PPC were retrospectively reviewed. Immuno-histochemical staining was used to detect PD-L1 expression, and PD-L1 status was classified into "high" or "low" according to the percentage of tumor cells (TCs) expressing PD-L1 (tumor proportion score, TPS).
RESULTS: PD-L1 expression was positive in 20 (76.9%) patients at the cut-off TPS value of 1%. A receiver-operating characteristic (ROC) analysis showed that the optimal cut-off value was 15% for prediction of cancer-specific death with the area under ROC curve of 0.701 (P = 0.107). High PD-L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer-specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD-L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054-1.200]; P = 0.084).
CONCLUSIONS: PD-L1 expression was positive in most PPC cases, and high PD-L1 expression may predict a favorable prognosis in resected PPC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  PD-L1; prognosis; pulmonary pleomorphic carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29601633     DOI: 10.1002/jso.25041

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

2.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

3.  The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.

Authors:  Tao Shi; Shuai Zhu; Hengjuan Guo; Xiongfei Li; Shikang Zhao; Yanye Wang; Xi Lei; Dingzhi Huang; Ling Peng; Ziming Li; Song Xu
Journal:  Front Oncol       Date:  2021-02-23       Impact factor: 6.244

4.  Ringed fluorodeoxyglucose uptake predicted poor prognosis after resection of pulmonary pleomorphic carcinoma.

Authors:  Yutaka Shishido; Akihiro Aoyama; Shigeo Hara; Yuki Sato; Keisuke Tomii; Hiroshi Hamakawa; Yutaka Takahashi
Journal:  J Cardiothorac Surg       Date:  2022-03-21       Impact factor: 1.637

5.  Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.

Authors:  Kazue Yoneda; Taiji Kuwata; Masatoshi Kanayama; Masataka Mori; Toshinori Kawanami; Kazuhiro Yatera; Takayuki Ohguri; Masanori Hisaoka; Toshiyuki Nakayama; Fumihiro Tanaka
Journal:  Br J Cancer       Date:  2019-08-07       Impact factor: 7.640

6.  Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy.

Authors:  Hao-Chun Chang; Chia-Lin Hsu; Yih-Leong Chang; Chong-Jen Yu
Journal:  Respirol Case Rep       Date:  2020-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.